Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 15/20 | 0.59 |
| ▸ | HTR4 | Q13639 | 15/20 | 0.59 |
| ▸ | PARP1 | P09874 | 2/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401326 | 1.00 | HTR3A (0.59) | HTR3AHTR4PARP1PARP2 | |
| SCHEMBL829163 | 0.90 | HTR4 (0.60) | HTR3AHTR4PARP1PARP2 | |
| SCHEMBL29399928 | 0.90 | HTR4 (0.60) | HTR3AHTR4PARP1PARP2 | |
| SCHEMBL29400942 | 0.88 | HTR3A (0.58) | HTR3AHTR4PARP1 | |
| SCHEMBL828465 | 0.88 | HTR3A (0.58) | HTR3AHTR4PARP1 | |
| SCHEMBL1728116 | 0.88 | HTR3A (0.45) | HTR3AHTR4PARP1 | |
| SCHEMBL829424 | 0.86 | HTR4 (0.76) | HTR3AHTR4PARP1PARP2 | |
| SCHEMBL1726779 | 0.85 | HTR3A (0.57) | HTR3AHTR4PARP1PARP2 | |
| SCHEMBL828472 | 0.85 | HTR3A (0.65) | HTR3AHTR4PARP1PARP2 | |
| SCHEMBL29397821 | 0.85 | HTR3A (0.65) | HTR3AHTR4PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899324-B1 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE INC (US) | 2011-11-30 | — | — | EP | claimed |
| US-8143279-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| EP-1899324-B1 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE INC (US) | 2011-11-30 | — | — | EP | disclosed |